Table 2.
KEGG pathways overrepresented by the upregulated DR genes in neonatal left ventricle with in utero exposure to increased maternal cortisol
| Pathways | No. of Genes Involved | Adjusted P Values | Genes |
|---|---|---|---|
| Pathways in cancer | 10 | 2.64E-05 | RALA, PPARD, GLI3, SMAD2, NRAS, BMP4, ARNT2, FZD2, COL4A6, SMAD4 |
| Wnt signaling pathway | 6 | 6.00E-04 | PPARD, SMAD2, FZD2, SFRP4, SMAD4, DAAM1 |
| Insulin signaling pathway | 5 | 3.30E-03 | CALM2, NRAS, EIF4E, PRKAR2A, CALM1 |
| TGF-β signaling pathway | 4 | 3.70E-03 | BMP4, SMAD2, BMP6, SMAD4 |
| Melanogenesis | 4 | 5.00E-03 | CALM2, NRAS, FZD2, CALM1 |
| Metabolic pathways | 12 | 6.50E-03 | NTPCR, PI4K2B, GSTZ1, POLR2I, CYP2CB, PAPSS2, P4HA2, UGDH, STT3B, ARSB, DHRS3, PANK3 |
| Basal cell carcinoma | 3 | 6.50E-03 | BMP4, GLI3, FZD2 |
| Hedgehog signaling pathway | 3 | 6.50E-03 | BMP4, GLI3, BMP6 |
| Cell cycle | 4 | 6.50E-03 | SMAD2, CDK7, CDC26, SMAD4 |
Pathways identified as over-represented by DR genes in CORT but not in the comparison of 142 days to newborn control hearts are shown in bold. CORT, cortisol; DR, differentially regulated; TGF, transforming growth factor.